NEW HEMOPHILIA INHIBITOR DRUG REACHES PHASE 3
March 4, 2014; Posted by: WeBleed staff
Factor VIIa hemophilia inhibitor drug reaches Phase 3 studies.
People who have encountered an inhibitor in their lifetime know how damaging it can be to the human body. With the advances in research and technology comes new products and medications to handle those inhibitors for people with hemophilia.
LFB S.A. announced that it’s biology subsidiary, rEVO Biologics, is entering a phase 3 program that will evaluate the efficacy and safety of it’s recombinant Factor VIIa drug.
“If proven safe and effective, LR769 (Factor VIIa) would provide doctors with the first new therapeutic option in more than 15 years for these difficult to treat hemophilia patients. Our goal is to bring therapeutic choice and innovative medicines to these patients,” Christian Béchon, Chairman and Chief Executive Officer, LFB S.A., was quoted in a News Medical press release today.
These studies are due to begin in 2015. Here’s to the hope that new medications reduce the complications of inhibitors in those with hemophilia.
Photo Credit – rEVO Biologics
webleed.org – your source for bleeding news!
